Unknown

Dataset Information

0

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.


ABSTRACT: Resistance to current therapies still impacts a significant number of melanoma patients and can be regulated by epigenetic alterations. Analysis of global cytosine methylation in a cohort of primary melanomas revealed a pattern of early demethylation associated with overexpression of oncogenic transcripts. Loss of methylation and associated overexpression of the CSF 1 receptor (CSF1R) was seen in a majority of tumors and was driven by an alternative, endogenous viral promoter in a subset of samples. CSF1R was particularly elevated in melanomas with BRAF and other MAPK activating mutations. Furthermore, rebound ERK activation after BRAF inhibition was associated with RUNX1-mediated further upregulation of CSF-1R and its ligand IL-34. Importantly, increased CSF-1R and IL-34 overexpression were detected in an independent cohort of resistant melanomas. Inhibition of CSF-1R kinase or decreased CSF-1R expression by RNAi reduced 3-D growth and invasiveness of melanoma cells. Coinhibition of CSF-1R and BRAF resulted in synergistic efficacy in vivo. To our knowledge, our data unveil a previously unknown role for the autocrine-regulated CSF-1R in BRAF V600E resistance and provide a preclinical rationale for targeting this pathway in melanoma.

SUBMITTER: Giricz O 

PROVIDER: S-EPMC6124424 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3388946 | BioStudies
2010-01-01 | S-EPMC3026446 | BioStudies
2015-01-01 | S-EPMC4432503 | BioStudies
2016-01-01 | S-EPMC5127567 | BioStudies
2008-01-01 | S-EPMC3808965 | BioStudies
1000-01-01 | S-EPMC3344978 | BioStudies
2013-01-01 | S-EPMC3579891 | BioStudies
2014-01-01 | S-EPMC4211983 | BioStudies
2008-01-01 | S-EPMC5543835 | BioStudies
1000-01-01 | S-EPMC3600451 | BioStudies